TCT-43 Final Five-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease

Friedrich Mohr; Simon Redwood; G E Venn; Antonio Colombo; Michael J. Mack; A. Pieter Kappetein; Marie‐Claude Morice; David R. Holmes; Ted Feldman; Elisabeth Ståhle; Keith D. Dawkins; Patrick W. Serruys

doi:10.1016/j.jacc.2012.08.052

Related publications

Article2012

TCT-42 Long-term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Left Main Disease: Final Five-year Follow-up of the SYNTAX Trial

Patrick W. Serruys, Grzegorz Religa, Witold Rużyłło, Elisabeth Ståhle, Antonio Colombo, Michael J. Mack, A. Pieter Kappetein, Marie‐Claude Morice, David R. Holmes, Ted Feldman, Keith D. Dawkins, Friedrich W. Mohr

Journal of the American College of Cardiology

Article2014

Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial

Stuart J. Head, Piroze Davierwala, Patrick W. Serruys, Simon Redwood, Antonio Colombo, Michael J. Mack, Marie‐Claude Morice, David R. Holmes, Ted Feldman, Elisabeth Ståhle, Paul Underwood, Keith D. Dawkins, A. Pieter Kappetein, Friedrich W. Mohr

European Heart Journal

Article2009

Optimal revascularization strategies in patients with total occlusions: 1-year results from the syntax trial

Patrick W. Serruys, Jacques Koolen, Ted Feldman, Michael J. Mack, Elisabeth Ståhle, David R. Holmes, A. Pieter Kappetein, Marie‐Claude Morice, Antonio Colombo, Katrin Leadley, Keith D. Dawkins, Friedrich W. Mohr

Cardiovascular revascularization medicine

Article2014

TCT-587 What if current generation drug-eluting stents were used in the SYNTAX trial? Analysis of the COMPARE and SYNTAX trials 5 year follow-up

Pieter C. Smits, Georgios J. Vlachojannis, Vasim Farooq, Patrick W. Serruys

Journal of the American College of Cardiology

Article2010

TWO-YEAR GRAFT OCCLUSION AND STENT THROMBOSIS IN PATIENTS WITH DE NOVO LEFT MAIN AND/OR THREE VESSEL DISEASE: ANALYSIS FROM THE SYNTAX TRIAL

Ted Feldman, Michael J. Mack, Antonio Colombo, Friedrich W. Mohr, Patrick W. Serruys, A. Pieter Kappetein, Thomas McGarry, Scott K. Lucas, Andrea Maria D’Armini, Ezio Bramucci, Katrin Leadley, Keith D. Dawkins

Journal of the American College of Cardiology

TCT-43 Final Five-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease

Abstract

Discussion(0)

Related publications

TCT-42 Long-term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Left Main Disease: Final Five-year Follow-up of the SYNTAX Trial

Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial

Optimal revascularization strategies in patients with total occlusions: 1-year results from the syntax trial

TCT-587 What if current generation drug-eluting stents were used in the SYNTAX trial? Analysis of the COMPARE and SYNTAX trials 5 year follow-up

TWO-YEAR GRAFT OCCLUSION AND STENT THROMBOSIS IN PATIENTS WITH DE NOVO LEFT MAIN AND/OR THREE VESSEL DISEASE: ANALYSIS FROM THE SYNTAX TRIAL